ORYZON to extend its R&D collaboration on ORY-1001 until March 2017

18 May 2016 BARCELONA, SPAIN and CAMBRIDGE MA. Oryzon Genomics (ISIN Code: ES0167733015), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and neurodegenerative diseases, announced today that the 2-year R&D collaboration with Roche concerning ORY-1001, licensed to Roche in 2014, has been extended until March 2017. Click here to see the full Press Release

The release as fetched from its publisher. oryzon.com ↗